Therefore, this study was aimed to analyze the status of the two best characterized genetic and epigenetic alterations of CRC (i.e., KRAS mutation and SEPT9 promoter methylation) in a cohort of CRC patients, in order to improve our understanding of the biological aspects modulating the concordance between tissues and plasma methylation and mutation profiles. Here, SEPTIN9 is linked to colorectal carcinoma.